Editas Medicine, Inc.
NASDAQ:EDITBiotechnology
+$0.07 today
- Market cap
- $281.67M
- Beta
- 2.10
- P/E (TTM)
- -2.4
- EPS (TTM)
- -$1.11
Volume 2.02M
Average 2.06M
Dividends
Editas Medicine, Inc. dividends
Review the payout history, yield, and how well earnings and cash flow support the dividend.
Dividends
Dividend history, growth & yield
Yield
0.00%
Annual Div/Share
$0.00
Payout Ratio
0.0%
Frequency
—
Shareholder Yield
0.00%
Next Ex-Date
Not announced
Next Payment
—
Analysis
The current indicated dividend yield is 0.00%. The payout ratio is 0.0%, so compare payout growth against earnings coverage.
Competitor dividends
How does Editas Medicine, Inc. compare as an income stock?
Compare dividend yield, payout ratios, and buybacks with similar companies.
Competitor Dividends
Peer payout, dividend, and buyback comparison
| Company | Market Cap | Dividend Yield | Annual Dividend | Payout Ratio | Buyback Yield |
|---|---|---|---|---|---|
CRISPR Therapeutics AG NASDAQ:CRSP | $4.10B | 0.00% | $0.00 | 0.00% | 0.00% |
Beam Therapeutics Inc. NASDAQ:BEAM | $2.36B | 0.00% | $0.00 | 0.00% | 0.00% |
Intellia Therapeutics, Inc. NASDAQ:NTLA | $1.36B | 0.00% | $0.00 | 0.00% | 0.00% |
Prime Medicine, Inc. NASDAQ:PRME | $774.48M | 0.00% | $0.00 | 0.00% | 0.00% |
Benitec Biopharma Inc. NASDAQ:BNTC | $315.40M | 0.00% | $0.00 | 0.00% | 0.00% |
Scribe Therapeutics Inc. NASDAQ:SCTX | $264.74M | — | $0.00 | — | 0.00% |
Rocket Pharmaceuticals, Inc. NASDAQ:RCKT | $252.48M | 0.00% | $0.00 | 0.00% | 0.00% |
Precision BioSciences, Inc. NASDAQ:DTIL | $211.33M | 0.00% | $0.00 | 0.00% | 0.00% |
Caribou Biosciences, Inc. NASDAQ:CRBU | $39.10M | 0.00% | $0.00 | 0.00% | 0.00% |
Questions
Dividend questions
Common questions about EDIT's dividend, answered from reported figures.
Does EDIT stock pay dividends?
Editas Medicine, Inc. (EDIT) currently pays a dividend. The indicated dividend per share is 0.00 USD and the dividend yield is 0.00%.
Is EDIT's dividend covered?
The payout ratio is 0.0%, so compare that against earnings and free cash flow before relying on the dividend.
Continue the stock analysis
Jump to another research area for this company.